The FDA this week announced that it’s mandating labeling changes to cut the use of prescription opioid cough and cold medicines containing codeine or hydrocodone in kids under 18 years of age.
The agency wrote in a statement that the risks of these drugs outweigh their potential benefits for children. The medications will also receive an expanded Boxed Warning notifying users about the risks of abuse, addiction and death.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA revises label on opioid cold meds to limit pediatric use appeared first on MassDevice.